Abstract
The splanchnic pharmacodynamic effects of the drugs used for the treatment of hemorrhagic complications of portal hypertension were poorly clarified until some years ago. The introduction of Doppler ultrasound provided a powerful tool to investigate such hemodynamic effects and brought new insights in this field. The present article reviews the pharmacodynamics of the substances used in the treatment of portal hypertension, with particular regard to the effects assessable by duplex Doppler ultrasonography.
MeSH terms
-
Adrenergic Agents / therapeutic use
-
Adrenergic beta-Antagonists / therapeutic use
-
Antihypertensive Agents / therapeutic use
-
Calcium Channel Blockers / therapeutic use
-
Diuretics / therapeutic use
-
Domperidone / therapeutic use
-
Humans
-
Hypertension, Portal / diagnostic imaging*
-
Hypertension, Portal / drug therapy*
-
Lypressin / analogs & derivatives
-
Lypressin / therapeutic use
-
Metoclopramide / therapeutic use
-
Nitrates / therapeutic use
-
Octreotide / therapeutic use
-
Portal System / diagnostic imaging*
-
Portal System / drug effects*
-
Somatostatin / therapeutic use
-
Terlipressin
-
Ultrasonography, Doppler*
-
Ultrasonography, Doppler, Duplex
-
Vasopressins / therapeutic use
Substances
-
Adrenergic Agents
-
Adrenergic beta-Antagonists
-
Antihypertensive Agents
-
Calcium Channel Blockers
-
Diuretics
-
Nitrates
-
Vasopressins
-
Lypressin
-
Somatostatin
-
Domperidone
-
Terlipressin
-
Metoclopramide
-
Octreotide